LuMind IDSC’s research priorities focus on medical conditions that disproportionately impact people with Down syndrome, such as Down syndrome related Alzheimer’s disease and sleep apnea. In addition, we support research projects in areas leading to increased independence and cognition for people with Down syndrome, including gene therapies.
What sets LuMind IDSC apart is the work we do to support the comprehensive enablement of clinical trials in the Down syndrome population. Establishing a durable and flexible structure that will allow people with Down syndrome to be included in clinical trials is a multi-step process. To that end, LuMind IDSC currently supports:
- a clinical trial network: DS-CTN.
- Advancing Down syndrome research: the gathering and analysis of natural history and biomarker data: LIFE-DSR
- a unique consortium of industry collaborators working collectively to advance Down syndrome research.
- the development of more effective assessment tools.
- channels of communication with regulators.
- efforts to prepare for clinical trial recruitment by raising awareness in the Down syndrome community
- a pipeline of information for our sister organizations and other Down syndrome foundations.
We focus on translational research. Our research strategy is rooted in ongoing collaboration and consultation with government agencies, research institutions, clinical practitioners, life science and pharmaceutical companies, and, most importantly, the Down syndrome community.
At the core of our research strategy are individuals with Down syndrome, their caregivers, and loved ones. Community readiness and participation are the key to achieving therapeutic, medical, and diagnostic advances for all.